NCT04635059

Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: Medical College of Wisconsin · Academic / Other
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a single-arm, open-label study using pacritinib for patients with histologically confirmed prostate adenocarcinoma, status post definitive treatment and biochemical recurrence.

Detailed description

This phase 2, single-arm, open-label study using pacritinib will treat patients with histologically confirmed prostate adenocarcinoma, status post definitive treatment and biochemical recurrence. The primary objective of this study is to determine the effect of pacritinib on the time to prostate-specific antigen (PSA) progression in patients with biochemical relapse of prostate cancer (defined as the length of time that a given subject will be alive and free from PSA progression per Prostate Cancer Working Group 3 (PCWG3) guidelines.

Conditions

• Prostate Cancer

Interventions

Type	Name	Description
DRUG	Pacritinib	Pacritinib is an oral drug which will be taken daily on a 28-day cycle at a dose of 200 mg twice a day (BID).

Timeline

• Start date: 2021-06-01
• Primary completion: 2023-11-30
• Completion: 2024-10-27
• First posted: 2020-11-18
• Last updated: 2025-11-17
• Results posted: 2024-12-17

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study